From June 3-6, 2024, the 2024 Biotechnology Innovation Organization International Convention (“BIO 2024”) was held at San Diego Convention Center in California, USA. Henlius, along with its wholly-owned subsidiary, Aton Biotech, a biologics CDMO, made a significant presence and showcased a wide range of innovative research and development accomplishments. Henlius presented 5 launched products and its product pipeline, attracting significant attention from numerous attendees and organizations.
During BIO 2024, Henlius hosted a successful experience sharing seminar themed "The Partner of Choice". The company's executives delivered keynote speeches on the cutting-edge practices and innovative solutions of Chinese Biopharma in the process of internationalization, which attracted widespread attention and recognition from the audience. Afterwards, the attendees participated in a panel discussion themed "Innovation spirit and partnership philosophy at Henlius", engaging in active interactions with enthusiastic responses. This exchange session provided a fantastic opportunity for Henlius to connect with valued business partners, showcasing the company's fruitful achievements in its internationalization process and further enhancing its influence in the global biopharmaceutical market.
Cao Ping, Senior Vice President and Chief Business Development Officer at Henlius, stated: “We concluded the conference with around 90 in-depth meetings for in-licensing, research collaboration, or commercial right out-licensing and a in-booth seminar, providing us the opportunity to engage in in-depth exchanges with leading global biopharmaceutical companies, investors, and partners. Together, we explored industry trends and discussed potential collaboration opportunities. Going forward, we will continue to work hand-in-hand with like-minded partners in the industry to drive progress and make affordable high-quality biologics accessible to patients worldwide.”
Having the goals of providing innovation and affordability for patient-centric unmet medical needs, Henlius has actively expanded the global markets by leveraging its strong product development, manufacturing and quality systems, and commercialization capabilities, as well as collaborating with capable partnerships to accelerate these goals. In late April this year, Henlius’ self-developed and -manufactured trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in U.S. and Zercepac® in Europe) receives FDA approval in the United States, becoming a China-developed mAb biosimilar approved in China, Europe, and U.S. It has been approved in over 40 countries and regions, covering Asia, Europe, Latin America, North America, and Oceania, benefiting over 190,000 patients. With the first shipment to the Middle East, HANQUYOU is poised to be the first Chinese monoclonal antibody to enter the Middle Eastern market.
Furthermore, adhering to a patient-centered and clinically-driven research and development philosophy, the company has proactively established a diversified and high-quality product pipeline. It covers various therapeutic areas, including oncology, autoimmune diseases, and ophthalmic disorders, with over 50 molecules in development, primarily focused on antibodies. The company actively explores new targets and mechanisms, continuously expanding its product portfolio in terms of therapeutic areas and novel molecule types. Recently, Henlius's investigational new drug application (IND) for phase 3 international multicenter clinical study of Henlius’novel anti-HER2 mAb, HLX22 has been approved by the United States Food and Drug Administration (FDA). Simultaneously, the company is making significant progress in the clinical development of two potential first/best-in-class products, HLX42 (EGFR ADC) and HLX43 (PD-L1 ADC). In terms of commercialization, the company has expanded its global market presence with eight products, including HANLIKANG, HANQUYOU, HANSIZHUANG, in collaboration with renowned international biopharmaceutical companies such as Accord, Abbott, Eurofarma, Elea, KGbio, and Organon. It has achieved comprehensive coverage in the mainstream biopharmaceutical markets of Europe, the United States, and numerous emerging markets, contributing to the global development of China's biopharmaceutical innovation.
Looking forward, Henlius will maintain its focus on unmet medical and market needs; develop more high-quality, affordable and innovative biologics; advance its global R&D, production, and commercialization capabilities; expand international collaborations, and accelerate building a global presence to benefit patients worldwide.